Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Hospital- and patient-related factors associated with differences in hospital antibiotic use: analysis of national surveillance results.

Haug JB, Berild D, Walberg M, Reikvam Å.

Antimicrob Resist Infect Control. 2014 Dec 24;3(1):40. doi: 10.1186/s13756-014-0040-5. eCollection 2014.

2.

[Aminoglycosides in severe sepsis].

Haug JB, Berild D, Blomberg B, Bruun JN, Flaatten HK, Leiva RA, Skrede S, Torfoss D, Undseth Ø.

Tidsskr Nor Laegeforen. 2013 Aug 20;133(15):1553-4. doi: 10.4045/tidsskr.13.0866. Norwegian. No abstract available.

3.

WHO defined daily doses versus hospital-adjusted defined daily doses: impact on results of antibiotic use surveillance.

Haug JB, Reikvam Å.

J Antimicrob Chemother. 2013 Dec;68(12):2940-7. doi: 10.1093/jac/dkt268. Epub 2013 Jul 9.

PMID:
23838948
4.

Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009.

Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P, Goossens H; ESAC-3 hospital care subproject group..

Clin Microbiol Infect. 2012 Oct;18(10):E389-95. doi: 10.1111/j.1469-0691.2012.03973.x. Epub 2012 Jul 24.

5.

Antimicrobial prescribing in hospitalized adults stratified by age: data from the ESAC point-prevalence surveys.

Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P, Goossens H; ESAC-3 Hospital Care Subproject Group..

Drugs Aging. 2012 Jan 1;29(1):53-62. doi: 10.2165/11597870-000000000-00000.

PMID:
22191723
6.

Pharmacy sales data versus ward stock accounting for the surveillance of broad-spectrum antibiotic use in hospitals.

Haug JB, Myhr R, Reikvam A.

BMC Med Res Methodol. 2011 Dec 13;11:166. doi: 10.1186/1471-2288-11-166.

7.

Increased antibiotic use in Norwegian hospitals despite a low antibiotic resistance rate.

Haug JB, Berild D, Walberg M, Reikvam A.

J Antimicrob Chemother. 2011 Nov;66(11):2643-6. doi: 10.1093/jac/dkr361. Epub 2011 Sep 7.

PMID:
21903657
8.

Identification of targets for quality improvement in antimicrobial prescribing: the web-based ESAC Point Prevalence Survey 2009.

Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P, Goossens H; ESAC-3 Hospital Care Subproject Group..

J Antimicrob Chemother. 2011 Feb;66(2):443-9. doi: 10.1093/jac/dkq430. Epub 2010 Nov 17.

PMID:
21084362
9.

European Surveillance of Antibiotic Consumption (ESAC) point prevalence survey 2008: paediatric antimicrobial prescribing in 32 hospitals of 21 European countries.

Amadeo B, Zarb P, Muller A, Drapier N, Vankerckhoven V, Rogues AM, Davey P, Goossens H; ESAC III Hospital Care Subproject Group..

J Antimicrob Chemother. 2010 Oct;65(10):2247-52. doi: 10.1093/jac/dkq309. Epub 2010 Aug 16.

PMID:
20713405
10.

["Look to Norway"--but for how long?].

Haug JB, Raastad R, Berild D.

Tidsskr Nor Laegeforen. 2010 Aug 12;130(15):1484-6. doi: 10.4045/tidsskr.10.0356. Norwegian.

11.

[Rational use of antibiotics in hospitals].

Berild D, Haug JB.

Tidsskr Nor Laegeforen. 2008 Oct 23;128(20):2335-9. Review. Norwegian.

12.

[Dangerous bacterial conditions].

Haug JB.

Tidsskr Nor Laegeforen. 2001 Nov 20;121(28):3262. Norwegian. No abstract available.

13.

Accuracy of IgG serology and other tests in confirming Helicobacter pylori eradication.

Lerang F, Haug JB, Moum B, Mowinckel P, Berge T, Ragnhildstveit E, Bjørneklett A.

Scand J Gastroenterol. 1998 Jul;33(7):710-5.

PMID:
9712234
14.

Accuracy of seven different tests for the diagnosis of Helicobacter pylori infection and the impact of H2-receptor antagonists on test results.

Lerang F, Moum B, Mowinckel P, Haug JB, Ragnhildstveit E, Berge T, Bjørneklett A.

Scand J Gastroenterol. 1998 Apr;33(4):364-9.

PMID:
9605257
15.

[Infectious endocarditis].

Haug JB.

Tidsskr Nor Laegeforen. 1998 Jan 20;118(2):213. Norwegian. No abstract available.

PMID:
9485613
16.

Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance.

Lerang F, Moum B, Ragnhildstveit E, Sandvei PK, Tolås P, Whist JE, Henriksen M, Haug JB, Berge T.

Am J Gastroenterol. 1998 Feb;93(2):212-6.

PMID:
9468244
17.

Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy.

Lerang F, Moum B, Haug JB, Berge T, Tolås P, Sandvei PK, Torp R, Tønnesen T.

Scand J Gastroenterol. 1997 Dec;32(12):1209-14.

PMID:
9438318
18.

A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.

Lerang F, Moum B, Ragnhildstveit E, Haug JB, Hauge T, Tolås P, Aubert E, Henriksen M, Efskind PS, Nicolaysen K, Søberg T, Odegaard A, Berge T.

Am J Gastroenterol. 1997 Apr;92(4):653-8.

PMID:
9128317
19.

Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?

Lerang F, Moum B, Haug JB, Tolås P, Breder O, Aubert E, Høie O, Søberg T, Flaaten B, Farup P, Berge T.

Am J Gastroenterol. 1997 Feb;92(2):248-53.

PMID:
9040200
20.

Bloodstream infections at a Norwegian university hospital, 1974-1979 and 1988-1989: changing etiology, clinical features, and outcome.

Haug JB, Harthug S, Kalager T, Digranes A, Solberg CO.

Clin Infect Dis. 1994 Aug;19(2):246-56.

PMID:
7986895

Supplemental Content

Loading ...
Support Center